Cargando…

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelia...

Descripción completa

Detalles Bibliográficos
Autores principales: Solly, Emma L., Dimasi, Catherine G., Bursill, Christina A., Psaltis, Peter J., Tan, Joanne T. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947565/
https://www.ncbi.nlm.nih.gov/pubmed/31847094
http://dx.doi.org/10.3390/jcm8122199
_version_ 1783485579664556032
author Solly, Emma L.
Dimasi, Catherine G.
Bursill, Christina A.
Psaltis, Peter J.
Tan, Joanne T. M.
author_facet Solly, Emma L.
Dimasi, Catherine G.
Bursill, Christina A.
Psaltis, Peter J.
Tan, Joanne T. M.
author_sort Solly, Emma L.
collection PubMed
description Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease.
format Online
Article
Text
id pubmed-6947565
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69475652020-01-13 MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis Solly, Emma L. Dimasi, Catherine G. Bursill, Christina A. Psaltis, Peter J. Tan, Joanne T. M. J Clin Med Review Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease. MDPI 2019-12-13 /pmc/articles/PMC6947565/ /pubmed/31847094 http://dx.doi.org/10.3390/jcm8122199 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Solly, Emma L.
Dimasi, Catherine G.
Bursill, Christina A.
Psaltis, Peter J.
Tan, Joanne T. M.
MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
title MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
title_full MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
title_fullStr MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
title_full_unstemmed MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
title_short MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis
title_sort micrornas as therapeutic targets and clinical biomarkers in atherosclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947565/
https://www.ncbi.nlm.nih.gov/pubmed/31847094
http://dx.doi.org/10.3390/jcm8122199
work_keys_str_mv AT sollyemmal micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis
AT dimasicatherineg micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis
AT bursillchristinaa micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis
AT psaltispeterj micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis
AT tanjoannetm micrornasastherapeutictargetsandclinicalbiomarkersinatherosclerosis